Heregulin induces expression, DNA binding activity and transactivating functions of basic leucine zipper activating transcription factor 4 by Talukder, Amjad H. et al.
[CANCER RESEARCH 60, 276–281, January 15, 2000
Advances in Brief
Heregulin Induces Expression, DNA Binding Activity, and Transactivating
Functions of Basic Leucine Zipper Activating Transcription Factor 41
Amjad H. Talukder, Ratna Vadlamudi, Mahitosh Mandal, and Rakesh Kumar2
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Abstract
Heregulin b1 (HRG), a combinatorial ligand for human epidermal
growth factor receptor 3 and human epidermal growth factor receptor 4
receptors, is a regulatory secretory polypeptide with distinct biological
effects such as growth stimulation, differentiation, invasiveness, and mi-
gration in breast cancer cells. The mechanism underlying the diverse
functions of HRG is not well established, but it is believed to be dependent
on the induced changes in expression of specific cellular gene products,
their modification, or both. The binding of basic leucine zipper transcrip-
tion factors to the cAMP response element is known to activate a variety
of gene products with a role or roles in growth regulation. In the studies
presented here, we identified basic leucine zipper activating transcription
factor (ATF) 4 as one of the HRG-inducible gene product. We demon-
strated that HRG stimulation of human cancer cells induces expression of
ATF4 mRNA and protein, ATF4 DNA binding activity, and ATF4 trans-
activating function. Consistent with its role as a transcriptional activator,
HRG-stimulated ATF4 protein stimulated the transcription from an ar-
tificial promoter with three tandem ATF sites or from a naturally occur-
ring promoter with ATF4 sites such as E-selectin. We also demonstrated
a preferential role of the HRG-stimulated mitogen-activated protein ki-
nase pathway, but not the phosphatidylinositol 3*-kinase pathway, in
supporting the observed increase in ATF4 DNA binding activity and
transcription from E-selectin promoter in HRG-stimulated cells. Because
ATF4 binding sites are present in a variety of growth-regulating cellular
genes, these findings suggest that the stimulation of ATF4 expression and
its transactivating functions may constitute an important mechanism of
HRG-mediated regulation of putative genes with diversified functions.
The present study is the first demonstration of regulation of expression
and transactivation ability of ATF4 by any polypeptide growth factor.
Introduction
Growth factors and their receptors play an essential role in the
regulation of epithelial cell proliferation. It has been demonstrated that
abnormalities in growth factor expression and action contribute to the
progression and maintenance of the malignant phenotype. For exam-
ple, c-erbB2 encodes HER2,3 the overexpression of which is fre-
quently associated with an aggressive clinical course and increased
metastasis in human breast cancer (1). Recently, additional members,
HER3 and HER4, have been added to the HER2 family because these
receptors also share sequence homology with the tyrosine kinase
domain of HER1 (2). The family receptors can be transactivated by
receptor-receptor interaction in a ligand-dependent manner and thus
can use more than one pathway to execute their biological functions
(2–4). In addition, accumulating evidence suggests that the progres-
sion of human breast cancer cells may be regulated by heregulin, a
combinatorial ligand for HER3 and HER4 receptors. Recently, we and
others (5–9) have demonstrated that HRG activation of breast cancer
cells (in the absence of HER2 overexpression) also promotes the
development of more aggressive phenotypes in breast cancer cells.
Although these observations suggest that ligand-driven activation of
HER receptors may play an important biological role or roles in the
progression of breast cancer cells to a malignant phenotype, the nature
of the pathways by which HRG signals are relayed to the nucleus in
breast cancer cells remains poorly understood.
It is widely believed that the induction of a set of early growth-
responsive (also known as immediately early) genes, in the absence of
de novo protein synthesis, may constitute the first step in the cellular
molecular response to extracellular signals. Transcription of protein-
coding genes is one of the major regulatory steps in gene expression.
Among the major regulatory elements that contribute to transcrip-
tional regulation of extracellular signals are the CRE and activator
protein 1 sequence motifs. The CRE element (TGACGTCA) is de-
fined as the ATF binding site. The process of transcription involves
physical interactions of sequence-specific DNA binding transcrip-
tional activations with general transcription factor directly, indirectly,
or both (10). It is increasingly accepted that the CRE site is recognized
by a family of the bZIP-containing proteins known as CREBs or
ATFs. The bZIP DNA-binding proteins need to dimerize for produc-
tive DNA binding (11). The dimeric bZIP factors are characterized by
a bipartite a-helical structure: the basic NH2-terminal half of the motif
interacts with sequence-specific DNA; whereas the COOH-terminal
half of the motif dimerizes to form a leucine zipper (11, 12). The bZIP
factors not only homodimerize but also heterodimerize with specific
bZIP proteins by the leucine zipper (12). Because binding sites for
ATF factors are present in several growth-regulating cellular promot-
ers (13), they are believed to be involved in different regulatory
circuits, allowing cells to integrate signals from distinct pathways. In
addition, the activity of ATF is also regulated by coactivators such as
CREB-binding protein/p300 family members (14). In the present
study, we have investigated the possible involvement of ATF proteins
in the action of HRG in breast cancer cells. We report that recombi-
nant HRG up-regulates the expression of bZIP transcription factor
ATF4, its DNA binding activity, and the ability of ATF4 to transac-
tivate the target genes in HRG-responsive cancer cells.
Materials and Methods
Cell Cultures and Reagents. Human breast cancer MCF-7 cells (8) and
colon cancer cell lines LS174T, CaC02, and FET (15) were maintained in
DMEM-Ham’s F-12 (1:1) supplemented with 10% FCS. Recombinant HRG
was purchased from Neomarkers, Inc., and anti-ATF4 Ab was purchased from
Santa Cruz, Inc.
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Cell Extracts and Immunoprecipitation. Cell lysates containing equal
amounts of protein were resolved by SDS-PAGE, transferred to nitrocellulose,
and probed with the appropriate Abs. An equal number of cells were meta-
bolically labeled for 12 h with 100 mCi/ml [35S]methionine in methionine-free
medium containing 2% dialyzed fetal bovine serum in the absence or presence
of HRG. Cell extracts (equal perceptible trichloroacetic acid counts) were
immunoprecipitated with the desired or control Ab, resolved on a SDS-PAGE
gel, and analyzed by autoradiography (16).
RT-PCR and Northern Hybridization. The sequences of the following
primers were obtained from the Clontech: (a) Tax, Tax-responsive enhancer
element-binding protein 107; (b) PUF, c-Myc purine-binding transcription
factor PUF; and (c) Mac, Merkes-related protein. The RT-PCR for ATFD and
others genes was done according to the manufacturer’s instructions using
access RT-PCR systems (Promega). The forward primer sequence for ATF4
was 59-AATGGCTGGC9rGTGGATGGG9I0I9GGTCA-39, and the reverse
primer sequence was 59-GATCATGGCAACGTAAGCAGTGTAGTCTG-39.
Human E-selectin-specific primers were purchased from R&D Systems. Total
cytoplasmic RNA was analyzed by Northern hybridization using an ATF4
cDNA probe (17) or a RT-PCR-generated 436-bp fragment. Ribosomal 28S
RNA and 18S RNA were used to assess the integrity of the RNA.
Nuclear Extract Preparation and Electrophoresis Mobility Shift Assay.
Nuclear extracts were prepared as described previously (18). The synthetic
oligonucleotides corresponding to the consensus sequence of human CRE
(59-AGAGATTGCCtGACGTCAGAGAGCTAG-39), activator protein 1 (59-
CGCTTGATGACTCAGCCGGAA-39), and nuclear factor kB (59-AGTT-
GAGGGGACTTTCCCAGG-39) were purchased from Santa Cruz, Inc. Oli-
gonucleotides were end-labeled with 32P by using the end-labeling kit
(Boehringer Mannheim). To confirm the ATF4 protein in the DNA-protein
complex, 5-mg extracts were incubated for 10 min with or without antisera
recognizing different nuclear factors.
Promoter Assays. Dr. T. Hai (Ohio State University, Columbus, OH)
generously provided pEC (ATF)3-CAT (19) and E-selection-CAT (20). Cells
were serum starved in low serum medium (0.1% serum) for 48 h before
transfection. Serum-starved cells were transiently cotransfected with ATF4
plasmid and a control vector using Lipofectamine (Life Technologies, Inc.).
CAT activity was measured 48 h after transfection using a CAT assay kit
(Promega).
Results
Identification of ATF4 as a HRG-inducible Gene. To better
understand the mechanism of HRG action in breast cancer cells, we
screened MCF-7 cells for HRG-inducible genes using the Atlas cDNA
Gene Array (Clontech). Total RNA was isolated from control and
HRG-treated cells, and cDNAs were generated by reverse tran-
scriptase in the presence of [a-32P]dCTP and hybridized to gene array
filters. This screening resulted in the identification of bZIP transcrip-
tion factor ATF4 as a HRG-inducible gene in breast cancer cells (Fig.
1A). To validate the results of RT-PCR screening, Northern blot
analysis was performed using a 406-bp PCR probe specific for ATF4.
Data in Fig. 1B demonstrate that HRG increased the steady-state
levels of the 1.6-kb mRNA of ATF4 by 2–4-fold in MCF-7 cells, with
maximal induction between 10 and 24 h after HRG treatment. Similar
results were obtained when the Northern hybridization was performed
using a human ATF4 cDNA (data not shown). Because there was no
precedent of growth factor-inducible up-regulation of ATF4, the ex-
periment was independently repeated five times, and similar results
were obtained.
HRG Regulates ATF4 at the Pretranslational Level. The ob-
served HRG-mediated increase in ATF4 mRNA could be due to
increased synthesis of newly transcribed mRNA, enhanced stability of
ATF4 mRNA, or both. To delineate this possibility, we examined the
effect of actinomycin D, an inhibitor of transcription. Pretreatment of
cells with actinomycin D abolished the HRG-mediated induction of
ATF4 mRNA, suggesting the need for continuous RNA synthesis in
the observed increased expression of ATF4 mRNA in HRG-treated
cells (Fig. 1C). To address the issue of translational regulation, we
used cycloheximide, a translational inhibitor. Treatment of cells with
cycloheximide by itself induced the expression of ATF mRNA (2–3-
fold). However, HRG treatment further induced the expression of
ATF4 mRNA compared with the level in cycloheximide-treated cul-
ture (compare Lane 3 with Lane 4). These results suggest that HRG
regulates ATF4 expression at a pretranslational level.
HRG Induces the Expression of Newly Synthesized ATF4 Pro-
tein and Its DNA Binding Activity. To determine whether the
observed increase in the level of ATF4 mRNA in HRG-treated
MCF-7 breast cancer cells was associated with an increase in the
expression of ATF4 protein, Western blot analysis was performed.
The results seen in Fig. 2A demonstrate that treatment of MCF-7 cells
with HRG was accompanied by a significant increase in the steady-
Fig. 1. HRG regulation of ATF4 mRNA expression.
A, identification of ATF4 as a HRG-inducible gene.
Tax, Tax-responsive enhancer element binding protein
107; PUF, c-Myc purine-binding transcription factor
PUF; Mac, Merkes-related protein; GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase. B, MCF-7 cells
were treated with HRG for the indicated times. Total
RNA (20 mg) was analyzed by Northern blotting using
a PCR-generated 436-bp human ATF4 fragment as a
probe. The blot was reprobed with a glyceraldehyde-3-
phosphate dehydrogenase cDNA probe. Quantitation of
ATF4 mRNA is shown in the bottom panel. The results
shown are representative of five independent experi-
ments. C, HRG induces ATF4 mRNA expression.
MCF-7 cells were treated with cycloheximide (50 mg/
ml) or actinomycin D (10 mg/ml) in the presence or
absence of HRG (10 ng/ml) for 3 h. Total RNA was
isolated, and the levels of ATF4 mRNA were detected
by Northern blotting. Quantitation of ATF4 mRNA is
shown in the bottom panel. Results shown are repre-
sentative of two independent experiments.
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state level of 250 kDa ATF4 protein. The observed HRG-mediated
increase in ATF4 expression was due to increased expression of
newly synthesized ATF4 in HRG-treated cells, as confirmed by met-
abolic labeling studies (Fig. 2B). There was no effect of HRG on the
half-life (,4 h) of ATF4 protein as assessed by pulse-chase experi-
ments (Fig. 2C).
To understand the physiological significance of ATF4 in HRG
activity in breast cancer cells, we investigated whether HRG signaling
could enhance the DNA binding of ATF4 to the CRE motif by using
a gel-shift assay. Data in Fig. 2D show that HRG treatment for 30 min
was associated with a significant enhancement of DNA binding ac-
tivity of ATF4 because this activity could be competed by wild-type
(Fig. 2D, Wt oligo) unlabeled CRE oligonucleotide but not by mutated
(Fig. 2D, Mt oligo) CRE oligonucleotide; the activity was blocked by
pretreatment of the nuclear extracts with a well-characterized anti-
ATF4 Ab (Ref. 17; Fig. 2D, the lower band is indicated by an arrow).
HRG Regulates ATF4 Expression and Its DNA Binding Activ-
ity in Diversified Cell Types. To determine whether the observed
induction of ATF4 expression is an effect restricted to HRG in MCF-7
cells or whether it could be demonstrated in other HRG-responsive
cells, we examined the effect of HRG on ATF4 expression in HRG-
responsive human colorectal LS174T, CaCO2, and FET cells (15). As
illustrated in Fig. 3, HRG treatment was associated with a significant
up-regulation of ATF4 mRNA expression in a number of HRG-
responsive cells (Fig. 3A) and also of ATF4 protein levels (Fig. 3B).
Although HRG could induce ATF4 expression and its DNA binding
activity in a number of human cell lines, we have chosen human breast
cancer MCF-7 cells as a model system to further ascertain the poten-
tial significance of ATF4 pathway in the regulation of HRG action.
Regulation of ATF4 Transactivation Functions by HRG. We
next determined whether HRG could activate CRE site-driven tran-
scription using a CAT reporter system. MCF-7 cells were transiently
transfected with a CAT reporter driven by artificial ATF sites
[p(ATF4)3 CAT] and stimulated with or without HRG. As illustrated
in Fig. 4A, HRG treatment stimulated the CAT reporter up to 3–5-fold
more than untreated control cells in a time-dependent manner. In
addition to activating the CAT reporter system driven by an artificial
promoter, HRG also stimulated the transcription from naturally oc-
curring promoters with ATF4 sites such as E-selection (19), although
to a lesser degree. In general, E-selectin promoter was about 2.6 times
less active, as compared to (ATF4)3 promoter. This may be related to
the fact that MCF-7 cells do not express E-selectin, probably due to
the presence of the appropriate transcription factors in the appropriate
places to drive full expression of the promoter. Results in Fig. 4B
demonstrate that HRG activated the E-selectin promoter, although to
a lesser extent than did the synthetic ATF4 promoter. It is possible that
HRG-induced ATF4 protein may not interact efficiently with the
natural promoter due to its interactions with other factors. Alterna-
tively, the observed activation may be sufficient to regulate the
expression of E-selectin mRNA. The putative role of HRG-induced
ATF4 in the stimulation of E-selectin promoter was confirmed by
cotransfection studies using a ATF4 plasmid or control vector. As
shown in Fig. 4C, cotransfection of MCF-7 cells with E-selectin CAT
with human pATF4-sense (Lanes 2 and 3), and not with pATF4-
antisense (Lane 4), resulted in a modest but significant stimulation of
promoter activity (Lane 3). Because MCF-7 cells do not express
E-selectin, we next examined whether HRG-mediated activation of
the E-selectin promoter could lead to up-regulation of E-selectin
mRNA in HUVECs. Results in Fig. 4D demonstrate that HRG treat-
ment of HUVECs was accompanied by stimulation of E-selectin
expression as determined by RT-PCR.
A Role of the MAPK Pathway in HRG-mediated ATF4 Trans-
activation. To understand the nature of signaling pathways leading to
ATF4 regulation, we next examined the potential involvement of
MAPK and PI-3K, two prototype signaling pathways that are widely
activated by growth factors. To demonstrate the functionality of these
pathways, MCF-7 cells were treated with or without HRG, and
stimulation of PI-3K and MAPK pathways was determined by thin-
layer chromatography and immunoblotting using phospho-p42/44 Ab,
respectively (Fig. 5A). In these studies, the activation of the MAPK
and PI-3K pathways was blocked by using well-characterized domi-
nant-negative mutants of MEKK (Ref. 21; upstream regulator of
Fig. 2. HRG up-regulates the level of ATF4 pro-
tein. A, MCF-7 cells were treated with HRG for the
indicated times. Total lysates were subjected to SDS-
PAGE and blotted with anti-ATF4 Ab (middle pan-
el). As an internal control, the upper portion of same
blot was probed with anti-FAK Ab (top panel).
Quantitation of ATF4 mRNA is shown in the bottom
panel. B, MCF-7 cells were stimulated with HRG for
12 h and metabolically labeled with [35S]methionine
during the last 4 h before harvesting. Cell lysates
were immunoprecipitated with an anti-ATF4 Ab and
analyzed by SDS-PAGE, followed by fluorography.
C, MCF-7 cells were metabolically labeled with
[35S]methionine for 2 h and cultured further in the
presence or absence of HRG for the indicated times.
Cell lysates were immunoprecipitated with an anti-
ATF4 Ab and analyzed by SDS-PAGE, followed by
fluorography. Results shown are representative of
three independent experiments. D, induction of
ATF4 DNA binding activity. Nuclear extracts were
incubated with a 32P-labeled oligonucleotide con-
taining the consensus CRE element for 30 min at
37°C. When indicated, nuclear extracts were prein-
cubated with a 50-fold excess of unlabeled wild-type
or mutated oligonucleotide and also by ATF4 Ab (2
or 4 ml) for 15 min. An arrow shows the specific
DNA-protein complex with which ATF4 Ab com-
peted. Results shown are representative of three in-
dependent experiments.
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MAPK) and the p85 subunit of PI-3K (8), respectively. As illustrated
in Fig. 5, B and C, there was no stimulatory effect of HRG on ATF4
DNA binding activity (Fig. 5B) and transactivation function (Fig. 5C)
in cells transfected with dominant-negative MEKK compared to con-
trol cells. In contrast, HRG stimulated both DNA binding activity
(Fig. 5B, Lanes 5 and 6) and transactivation function (Fig. 5C, Lanes
5 and 6) of ATF4 in cells expressing dominant-negative p85. In brief,
these results suggest a potential role of MAPK in regulation of ATF4
transactivation in HRG-treated breast cancer cells.
Discussion
HRG has been shown to modulate the growth, differentiation, and
motility of breast cancer cells. The multifunctional nature of HRG is
thought to be dependent on the induced changes in expression, mod-
ification, or both of specific cellular gene products. Because we
identified the bZIP transcription factor ATF4 as one of the HRG-
inducible genes and because the binding sites for ATF4, the CRE
element, are commonly present in genes that regulate cell growth, we
explored the possible involvement of ATF protein in the action of
HRG using human breast cancer MCF-7 cells as a model system.
The results presented here indicate that treatment of human cells
with HRG induced significantly induced higher levels of ATF4 pro-
tein expression. The expression and induction of ATF4 protein by
HRG open a whole new area of investigation regarding the role of
bZIP transcription factor in HRG activity. These observations, to-
gether with the fact that ATF4 promoter itself contains CRE sites (22),
raise the possibility of an autoregulatory role of increased ATF4 DNA
binding activity in the induction of ATF4 expression in HRG-stimu-
lated cells.
Our conclusion that HRG is a very potent inducer of ATF4 expres-
sion is supported by the following lines of evidence: (a) HRG stim-
ulated the expression of ATF4 mRNA as early as 3 h after treatment;
(b) elevated expression of ATF4 mRNA was sensitive to the tran-
scriptional inhibitor; (c) HRG-mediated increased expression of ATF4
mRNA was accompanied by the enhancement of ATF4 protein; and
(d) HRG stimulated the expression of newly synthesized 35S-labeled
ATF4 protein. These findings establish that ATF4 is a bona fide
HRG-inducible gene product. The induction of ATF4 expression by
HRG was not a phenomenon restricted to MCF-7 cells because HRG
also induces the expression of ATF4 mRNA and protein in other
HRG-responsive human tumor cell lines, such as colon carcinoma,
FET, and CaCO2 cells (15).
Another notable finding of this study is the potential role of HRG-
initiated signals in transcriptional activation of genes containing CRE
sites including ATF4 and E-selectin (19). The evidence that cotrans-
Fig. 3. HRG stimulates ATF4 expression in multiple cell lines. A, FET, CaC02, and
LS174T colon cancer cell lines were treated with or without HRG for the indicated times,
and ATF4 mRNA expression was determined by Northern blotting. The blot was sequen-
tially reprobed with a glyceraldehyde-3-phosphate dehydrogenase probe (GAPDH). B,
lysates from control and HRG-treated FET cells were analyzed by Western blotting using
ATF4 mAb. Results shown are representative of two independent experiments.
Fig. 4. Regulation of ATF4 transactivation func-
tions by HRG. A and B, MCF-7 cells were transiently
transfected with p(ATF)3-CAT (A) or E-selectin CAT
(B) constructs, and CAT activity was measured after
36 h of transfection. Some cultures were treated with
HRG for 4 or 24 h before lysis. These studies were
independently repeated four times with similar results.
Quantitative means of four experiments are shown in
the bottom panel. C, MCF-7 cells were transfected
with E-selectin-CAT in the absence (Lane 1) or pres-
ence of human ATF4-sense (Lanes 2 and 3) or human
ATF4-antisense (Lane 4). Results shown are repre-
sentative of three separate experiments. D, HUVECs
were treated with HRG or tumor necrosis factor a (as
a positive control), and total RNA was analyzed by
RT-PCR for E-selectin mRNA expression (485-bp
product).
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fection of human ATF4 has the capacity to activate E-selectin pro-
moter-driven transcription is of special interest because it strongly
suggests that HRG-induced ATF4 expression may contribute in the
modulation of expression of genes containing ATF4 binding sites
either directly, indirectly, or both by influencing the physical interac-
tions between ATF4 and its binding factors. Data from the literature
suggest that up-regulation of E-selectin expression in endothelial cells
may be closely associated with increased metastases and invasion of
human breast cancer cells (23). Because HRG is a paracrine growth
factor, our preliminary finding of HRG-mediated stimulation of E-
selectin expression in HUVECs implies that HRG may use the ATF4
transcription factor to regulate the expression of gene products with a
role in breast cancer progression to a more invasive phenotype.
Data from the literature suggest that in addition to transactivation,
ATF4 may also act as a transcriptional repressor, presumably due to
sequestration of factors and cofactors from the proximity of the target
promoter (10, 11). In view of these earlier findings, it seems reason-
able to speculate that HRG may also use inducible modification of
ATF4 to potentially repress the expression of unidentified cellular
genes that negatively regulate the invasiveness of breast cancer cells.
Although we demonstrated the stimulation of E-selectin as an exam-
ple of transcription activation of a cellular gene by bZIP transcription
factor ATF4 in HRG-treated cells, our findings may have a general
implication for regulation of cellular genes with a CRE motif by
HRG-inducible signals. In the present study, we have not identified
the nature of ATF4 target genes in HRG-stimulated cells. Another
emerging concept from our present investigation is the possibility that
HRG regulation of ATF4 may provide an explanation for multiple
cellular functions of HRG because binding sites for the ATF4 factor
are present in several growth-regulating cellular promoters and be-
cause ATF4-interacting factors, particularly CREB-binding protein/
p300, are widely believed to be involved in integrating regulatory
signals from distinct pathways (13). Together, these events may lead
to differential regulation of genes that may participate in the media-
tion of HRG in breast cancer cells.
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